EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Xlife Sciences AG's Enterprise Value is €283.69 Mil.
Xlife Sciences AG's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.96 Mil. Therefore, Xlife Sciences AG's EV-to-FCF for today is -294.58.
The historical rank and industry rank for Xlife Sciences AG's EV-to-FCF or its related term are showing as below:
FRA:XLS'
s EV-to-FCF Range Over the Past 10 Years
Min: -777.9 Med: -88.87 Max: 3945.17
Current: -289.35
During the past 8 years, the highest EV-to-FCF of Xlife Sciences AG was 3945.17. The lowest was -777.90. And the median was -88.87.
FRA:XLS's EV-to-FCF is ranked worse than 100% of 336
companies
in the Biotechnology industry
Industry Median: 14.7
vs FRA:XLS: -289.35
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Xlife Sciences AG's PE Ratio (TTM) for today is calculated as:
Xlife Sciences AG's share price for today is €21.60.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Xlife Sciences AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-4.026.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Xlife Sciences AG EV-to-FCF Related Terms
Xlife Sciences AG EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Xlife Sciences AG's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Xlife Sciences AG's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xlife Sciences AG EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xlife Sciences AG's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Xlife Sciences AG's EV-to-FCF falls into.
Xlife Sciences AG's current Enterprise Value is €283.69 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Xlife Sciences AG's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.96 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xlife Sciences AG (FRA:XLS) has a EV-to-FCF of -294.58 as of Jun. 29, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Xlife Sciences AG and its competitors. According to the industry distribution chart, Xlife Sciences AG ranks #999999 out of 336 companies in the Biotechnology industry.
Is Xlife Sciences AG's EV-to-FCF too high?
Xlife Sciences AG's current EV-to-FCF is -294.58. Based on the distribution chart, Xlife Sciences AG ranks #999999 out of 336 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Xlife Sciences AG has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xlife Sciences AG's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Xlife Sciences AG ranks #999999 out of 336 companies for EV-to-FCF. This places Xlife Sciences AG in the lower half of its industry. The industry median EV-to-FCF is 14.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.70, based on 336 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Xlife Sciences AG and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xlife Sciences AG's current EV-to-FCF is -294.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xlife Sciences AG stock overvalued right now?
Based on GuruFocus' analysis, Xlife Sciences AG (FRA:XLS) is currently considered Significantly Overvalued. The stock's GF Value™ is €7.80, compared to a current price of €21.60 — trading 176.9% above its estimated fair value. The current EV-to-FCF is -294.58. Xlife Sciences AG's overall GF Score™ is 56/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Xlife Sciences AG (FRA:XLS), the current EV-to-FCF is -294.58 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xlife Sciences AG (FRA:XLS) Overvalued in 2026?
Based on GuruFocus' analysis, Xlife Sciences AG stock appears to be overvalued.
The current stock price of €21.60 is trading 176.9% above its estimated GF Value™ of €7.80.
GuruFocus considers Xlife Sciences AG to be Significantly Overvalued.
Key valuation signals for FRA:XLS:
EV-to-FCF: -294.58
GF Value™: €7.80 vs. price of €21.60 (176.9% above fair value)
No single metric tells the full story. See the FRA:XLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.
56GF Score
Get the complete analysis for FRA:XLS
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:XLS has been successfully added to your 
